Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
1.396 Leser
Artikel bewerten:
(2)

Abbott's Freestyle Libre Is Named Best Medical Technology in Last 50 Years by the Galien Foundation

Finanznachrichten News
  • Abbott's FreeStyle Libre honored as the "best of the best" since 1970 during the Prix Galien Golden Jubilee Awards
  • Revolutionary FreeStyle Libre technology has transformed the lives of approximately 4.5 million people (1) living with diabetes globally

ABBOTT PARK, IL / ACCESSWIRE / December 23, 2022 / The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre® continuous glucose monitoring technology as the "Best Medical Technology" of the last 50 years during its Prix Galien Golden Jubilee Awards ceremony on Oct. 27 in New York City. The Prix Galien Golden Jubilee Awards recognize global innovations that have had the greatest impact on society since the Galien Foundation was founded in 1970.

Award winners were chosen across five categories from the 250 products awarded the Prix Galien, regarded as the equivalent of the Nobel Prize for biopharmaceutical and medical technology research, between 1970 and 2019. The FreeStyle Libre system was awarded the 2019 Prix Galien USA Award for Best Medical Technology.

"Abbott's FreeStyle Libre portfolio has revolutionized how people live with diabetes, eliminating the need for traditional fingersticks,(2)" said Jared Watkin, senior vice president of Abbott's diabetes care business. "Today, approximately 4.5 million people around the world use this life-changing technology to manage their diabetes and improve health outcomes, helping them live fuller, healthier lives every day."

"The Prix Galien Golden Jubilee Awards honor the global 'best of the best' innovations that have improved the human condition over the last 50 years," said Bruno Cohen, Chairman of the Galien Foundation. "The companies behind these amazing innovations have a bold passion for change, which has led to the development of life-saving products."

Over the years, Abbott has received 11 Prix Galien Awards for its innovations in pharmaceuticals and medical technology, including for Humira, MitraClip and FreeStyle Libre.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with Abbott at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Indications and Important Safety Information

FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.

FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.

For U.S. important safety information on MitraClip, visit http://abbo.tt/MitraClipG4ISI.

(1) Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre portfolio compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.
(2) Data on file, Abbott Diabetes Care. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

For further information: Abbott Media: Lindsy Delco, (510) 239-2690; Abbott Financial: Mike Comilla, (224) 668-1872

View additional multimedia and more ESG storytelling from Abbott on 3blmedia.com.

Contact Info:
Spokesperson: Abbott
Website: www.abbott.com
Email: info@3blmedia.com

SOURCE: Abbott

View source version on accesswire.com:
https://www.accesswire.com/733172/Abbotts-Freestyle-Libre-Is-Named-Best-Medical-Technology-in-Last-50-Years-by-the-Galien-Foundation

© 2022 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.